MY136322A - Anthranilic acid amides and pharmaceutical use thereof - Google Patents

Anthranilic acid amides and pharmaceutical use thereof

Info

Publication number
MY136322A
MY136322A MYPI20024160A MYPI20024160A MY136322A MY 136322 A MY136322 A MY 136322A MY PI20024160 A MYPI20024160 A MY PI20024160A MY PI20024160 A MYPI20024160 A MY PI20024160A MY 136322 A MY136322 A MY 136322A
Authority
MY
Malaysia
Prior art keywords
treatment
anthranilic acid
c7alkyl
lower alkyl
acid amides
Prior art date
Application number
MYPI20024160A
Other languages
English (en)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY136322A publication Critical patent/MY136322A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
MYPI20024160A 2001-11-08 2002-11-07 Anthranilic acid amides and pharmaceutical use thereof MY136322A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126901.8A GB0126901D0 (en) 2001-11-08 2001-11-08 Organic compounds
GBGB0212917.9A GB0212917D0 (en) 2001-11-08 2002-06-05 Organic compounds

Publications (1)

Publication Number Publication Date
MY136322A true MY136322A (en) 2008-09-30

Family

ID=26246753

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024160A MY136322A (en) 2001-11-08 2002-11-07 Anthranilic acid amides and pharmaceutical use thereof

Country Status (25)

Country Link
US (1) US7067543B2 (enExample)
EP (2) EP2269988B1 (enExample)
JP (1) JP4179989B2 (enExample)
KR (1) KR100633814B1 (enExample)
CN (1) CN100467450C (enExample)
AR (1) AR037261A1 (enExample)
AT (1) ATE494278T1 (enExample)
AU (1) AU2002342889B2 (enExample)
BR (1) BR0213939A (enExample)
CA (1) CA2462390C (enExample)
DE (1) DE60238856D1 (enExample)
GB (2) GB0126901D0 (enExample)
HR (1) HRP20040412A2 (enExample)
IL (1) IL161163A0 (enExample)
MX (1) MXPA04004390A (enExample)
MY (1) MY136322A (enExample)
NO (1) NO326986B1 (enExample)
NZ (1) NZ532587A (enExample)
PE (1) PE20030540A1 (enExample)
PL (1) PL368417A1 (enExample)
PT (1) PT1446381E (enExample)
RS (1) RS29404A (enExample)
RU (1) RU2315756C2 (enExample)
TW (1) TWI260985B (enExample)
WO (1) WO2003040101A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
ES2619203T3 (es) 2004-01-28 2017-06-23 Mitsui Chemicals Agro, Inc. Derivados de amida, procesos para la producción de los mismos y método para su aplicación como insecticidas
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CA2155662A1 (en) * 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RS29404A (sr) 2007-02-05
NO20042137L (no) 2004-05-25
EP2269988A2 (en) 2011-01-05
RU2315756C2 (ru) 2008-01-27
HRP20040412A2 (en) 2005-06-30
DE60238856D1 (de) 2011-02-17
IL161163A0 (en) 2004-08-31
EP1446381A1 (en) 2004-08-18
TWI260985B (en) 2006-09-01
KR100633814B1 (ko) 2006-10-13
JP2005508382A (ja) 2005-03-31
PT1446381E (pt) 2011-01-31
KR20050044374A (ko) 2005-05-12
TW200300086A (en) 2003-05-16
AR037261A1 (es) 2004-11-03
GB0212917D0 (en) 2002-07-17
NO326986B1 (no) 2009-03-30
EP1446381B1 (en) 2011-01-05
CA2462390C (en) 2011-01-11
PE20030540A1 (es) 2003-08-05
CA2462390A1 (en) 2003-05-15
EP2269988B1 (en) 2012-05-23
US20040248947A1 (en) 2004-12-09
JP4179989B2 (ja) 2008-11-12
MXPA04004390A (es) 2005-05-16
RU2004117548A (ru) 2005-06-10
ATE494278T1 (de) 2011-01-15
US7067543B2 (en) 2006-06-27
EP2269988A3 (en) 2011-02-16
WO2003040101A1 (en) 2003-05-15
PL368417A1 (en) 2005-03-21
NZ532587A (en) 2006-02-24
CN100467450C (zh) 2009-03-11
GB0126901D0 (en) 2002-01-02
CN1578768A (zh) 2005-02-09
AU2002342889B2 (en) 2007-03-01
BR0213939A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
GB0126902D0 (en) Organic compounds
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
CN101815514B (zh) 磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP2269988A3 (en) Anthranilic acid amides and pharmaceutical use thereof
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
PT1572686E (pt) Derivados de amida do ácido antranílico e suas utilizações farmacêuticas
ECSP045091A (es) Amidas de acido antranilico y uso farmaceutico de las mismas
MXPA04012685A (es) Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
ECSP045092A (es) Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
TH88080A (th) แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน
UY27534A1 (es) Amidas de ácido antranílico y uso farmacológico de las mismas.
HK40037132B (en) Method of treatment with histamine-3 receptor inverse agonist
TH58659A (th) อนุพันธ์ของเฟนอกซิแอซีทิคแอซิด และองค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยสารชนิดเดียวกันนั้น